Less than 30% of FDA-cleared AI devices shared key safety and adverse event data before approval, raising regulatory concerns.
Key Details
- 1A new analysis reviewed FDA approval and recall databases for all AI/ML devices cleared from 1995 to July 2023.
- 2Of 691 devices analyzed, 531 targeted radiology applications.
- 3Fewer than 30% of devices provided data on safety, efficacy, or adverse events prior to approval.
- 4No predefined efficacy or safety reporting standards currently exist for AI/ML devices in the U.S., unlike with pharmaceuticals.
- 5The findings highlight a regulatory gap and call for stricter testing and dedicated approval pathways for AI/ML-based medical devices.
Why It Matters
This research underscores a major gap in regulatory standards and transparency for AI devices in radiology, potentially impacting patient safety and trust. Addressing these concerns could lead to more robust evidence and safer adoption of AI in clinical imaging practice.
Source
Radiology Business
Related News
•Radiology Business
Radiologists Prefer Domain-Specific AI for CT Report Generation
Radiologists show a clear preference for domain-specific AI models in generating accurate and timely CT report impressions.
•AuntMinnie
Radiology Receives Declining Share of Industry Research Funding
Radiologists received only 1.1% of industry-funded research payments in 2024, with a continuing downward trend.
•AuntMinnie
GPT-4o AI Matches Radiologists in Follow-Up Imaging Recommendations
GPT-4o matched the performance of experienced radiologists and surpassed residents in recommending follow-up imaging from routine radiology reports.